A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Qiao, N. [1 ]
Insinga, R. [2 ]
Burke, T. [3 ]
Lopes, G. [4 ,5 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Merck & Co Inc, West Point, PA USA
[3] Merck & Co Inc, Cokesbury, NJ USA
[4] Univ Miami, Miami, FL USA
[5] Miller Sch Med, Miami, FL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [1] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Nan Qiao
    Ralph Insinga
    Gilberto de Lima Lopes Junior
    John Cook
    Martin Sénécal
    [J]. PharmacoEconomics - Open, 2021, 5 : 365 - 383
  • [2] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Qiao, Nan
    Insinga, Ralph
    Lopes Junior, Gilberto de Lima
    Cook, John
    Senecal, Martin
    [J]. PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 365 - 383
  • [3] Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review
    Zhang, Chuan
    Zhang, Jiaxu
    Tan, Jing
    Tian, Panwen
    Li, Weimin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [5] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [6] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    [J]. LUNG CANCER, 2018, 124 : 248 - 254
  • [7] Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
    Criss, Steven D.
    Palazzo, Lauren
    Watson, Tina R.
    Paquette, Adelle M.
    Sigel, Keith
    Wisnivesky, Juan
    Kong, Chung Yin
    [J]. PLOS ONE, 2020, 15 (01):
  • [8] Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer
    Szczepura, A
    [J]. LUNG CANCER, 2002, 38 : S21 - S28
  • [9] COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL
    Almeida, J.
    Tavares, A.
    Vandewalle, B.
    Falix, J.
    Andreozzi, V
    Viana, D. S.
    [J]. VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CARCINOMA IN PORTUGAL
    Pinheiro, B. A.
    Alarcao, J.
    Silva Miguel, L.
    Huang, M.
    Chandwani, S.
    Vargas Lopes, F.
    Borges, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A432 - A432
12345